HER2陽性転移性大腸癌の一次治療におけるツカチニブとトラスツズマブおよびmFOLFOX6の併用療法と標準治療との比較試験

基本情報

NCT ID

NCT05253651

ステータス

募集中

試験のフェーズ

第3相

試験タイプ

介入

目標被験者数

400

治験依頼者名

Seagen Inc.

概要

This study is being done to find out if tucatinib with other cancer drugs works better than standard of care to treat participants with HER2 positive colorectal cancer. This study will also determine what side effects happen when participants take this combination of drugs. A side effect is anything a drug does to the body besides treating your disease. Participants in this study have colorectal cancer that has spread through the body (metastatic) and/or cannot be removed with surgery (unresectable). Participants will be assigned randomly to the tucatinib group or standard of care group. The tucatinib group will get tucatinib, trastuzumab, and mFOLFOX6. The standard of care group will get either: * mFOLFOX6 alone, * mFOLFOX6 with bevacizumab, or * mFOLFOX6 with cetuximab mFOLFOX6 is a combination of multiple drugs. All of the drugs given in this study are used to treat this type of cancer.

対象疾患

介入

依頼者（Sponsor）

実施施設 (16)